Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Wed, 26.05.2021
Aspermont Limited
Aspermont is the leading media services provider to the global resource
industries. Aspermont has invested 20 years in building a commercial model
for B2B media that is founded on providing high value content to a
globalsubscriber base. Aspermont is scaling this B2B model to serve new
sectors and new countries and in new languages to maintain glob [ … ]
Fri, 21.05.2021
Saturn Oil & Gas Inc.
Transformative transaction increasing oil production from 350 boe/d to over
7,200
Prime assets with proven low depletion rates. The company is cur-rently
completing the Oxbow assets acquisition, which is located in the Williston
Basin oil field. The company's new inventory will consist of low decline
oil wells with very low gas volumes (5%), thu [ … ]
Tue, 18.05.2021
Saturn Oil & Gas Inc.
'Oxbow acquisition is transformative and will transform Saturn Oil & Gas
into a leading producer and land holder throughout Saskatchewan'
Saturn Oil & Gas acquires the Oxbow asset
Saturn Oil & Gas has entered into an agreement to purchase the Oxbow assets
for approximately 93M CAD. The Oxbow's assets are located in Southeast
Saskat [ … ]
Fri, 14.05.2021
Saturn Oil & Gas Inc.
'Oxbow acquisition is transformative for Saturn and will transform us into
a leading producer and land holder throughout Saskatchewan '
GBC AG: Mr. Jeffrey, you have just announced a massive transaction. Can you
explain us how transformative this moment is for the future of the company?
John Jeffrey: The magnitude of this transaction is enormo [ … ]
Wed, 12.05.2021
SYZYGY AG
Visible revenue growth of foreign subsidiaries; German SYZYGY companies
with positive trend; new record Q1 EBIT achieved; forecasts and price
target of EUR9.60 confirmed; Rating: BUY
In the first quarter of 2021, SYZYGY AG generated moderate revenue growth
of 0.9% with total revenue of EUR15.06 million (previous year: EUR14.93
million). Although [ … ]
Tue, 11.05.2021
Media and Games Invest plc
Capital increase for growth financing successfully carried out;
continuation of dynamic growth course expected; oversubscribed capital
measure opens up significant inorganic growth potential; price target
lowered to EUR 6.92 (previously: EUR 7.35) due to the dilution effect that
has occurred.
Successful capital increase for consistent implementa [ … ]
Mon, 10.05.2021
Cryptology Asset Group PLC
Cryptology Asset Group: 'We want to be the leading European investor in
crypto assets and blockchain-based business models'
Cryptology Asset Group is a publicly traded investment company focused on
cryp-to-assets and blockchain-based business models. For this purpose,
Cryptology has a broad network of experts, including Christian Angermayer
and [ … ]
Tue, 04.05.2021
Media and Games Invest plc
Jump in revenue and earnings in the first quarter of 2021; the largest
growth pipeline in the company's history ensures further dynamic growth;
the expected recovery of the advertising market offers additional growth
potential for the Group's own digital advertising division, increase in
forecasts and price target
Turnover and earnings developme [ … ]
Thu, 29.04.2021
MagForce AG
Further results of the pivotal study 2a confirm expectations, market
approval in 2021 still in prospect, price target of EUR 11.00 and BUY
rating confirmed
After MagForce AG announced the successful completion of stage 2a of the
pivotal study for the treatment of prostate cancer in the USA in February
2021, the company has published additional, [ … ]
Thu, 22.04.2021
Cardiol Therapeutics
The Company announced topline results from its Phase I Single and Multiple
Ascending Dose Clinical Trial of CardiolRx(TM). CardiolRx is a
pharmaceutically produced oral cannabidiol formulation being developed for
the treatment of acute and chronic inflammation associated with heart
disease. These results positively support Cardiol Therapeutics' pr [ … ]